Global Literature Screening
Global literature screening is one of the key pharmacovigilance obligations you have. Depending on what your portfolio is, it can either be one of the easiest tasks or one of the most time-consuming ones. Either way, Tepsivo literature monitoring service can fully cover your regulatory duties.
Do you have one or a handful of products on the market?
First things first. Let us check if your substance isn’t already monitored by EMA’s Medical Literature Monitoring service. If yes, then there is no reason to duplicate the effort. To its credit, EMA has gone in the right direction by centralizing the screening in one place for many substances.
If your substance isn’t monitored centrally by EMA, you will need someone to screen the databases weekly and track any relevant results. That’s what we can easily do. Thanks to our automated Tepsivo Platform, it’s very easy for us to track and report any outputs of the screening, further dropping down the total price.
Do you have a large portfolio of products?
If you represent a generic company with a large portfolio, the global literature screening may in fact become a colossal cost for you. Here is where you need to automate.
We’ve spent a lot of time going through the best possible options how to optimize literature monitoring and decrease the associated time effort and cost. Reach out to us to discuss your situation and we’ll prepare the most fitting solution for you. Most likely a combination of an AI-powered search tool and our inhouse Tepsivo Platform, automating both the screening time as well as the reporting side of the process.
What makes us special?
Our pragmatism and belief in efficiency in contrast to greed.
It is our view that local literature screening in non-indexed journals is an outdated requirement, and it shouldn’t really exist in today’s world, at least not in the form it is required now. That is, if we believe that pharmacovigilance process effectiveness should be a measurement of quality.
If you’re present globally, local literature screening will constitute a large part of your PV budget. We’ve been making arguments to the EMA to remove this requirement but to no avail. It’s here to stay and local literature screening will remain expensive for pharmaceutical companies.
So if EMA and legislators are not taking action, what can we do?
We can automate the process and heavily bring down your total costs.
Our unique Tepsivo Literature searches through thousands of sources based on keywords and sends auto-translated abstracts to one central place that is Tepsivo Platform. All with 0 people trapped doing mundane activities.
Plus, thanks to Tepsivo Platform, we removed the traditionally heavy work in reporting/tracking/reconciling that usually adds so much extra time effort to an already time intense activity. Especially in global operations.
For traditional pharmacovigilance providers and CROs, local literature monitoring is a financially lucrative activity. But we’re not greedy, we don’t believe that it belongs, in its current form, to the field and it certainly doesn’t meet the criteria of what we see as value-based healthcare. That is what we developed Tepsivo Literature, saving time and money on meaningless tasks
Want to learn more?
Let’s have a chat
Whatever you needs are, we look forward to getting in touch with you.
Feel free to drop us a message and we will contact you right away.